RetinalGenix Technologies Agrees To Hire M. Cory Zwerling as CFO, Interim COO

Rhea-AI Summary

RetinalGenix (OTCQB: RTGN) agreed to hire M. Cory Zwerling as chief financial officer and interim chief operating officer, effective January 1, 2026. The company said Zwerling brings more than three decades of global healthcare, finance, and operations experience across pharmaceuticals, medical imaging, biotechnology, and digital health.

Management describes his background in big‑pharma P&L leadership, medtech start‑up execution, AI/health IT, and public‑company governance as aligned to RetinalGenix’s transition from R&D toward an intended commercial launch, with responsibilities including reimbursement strategy, clinical development coordination, and disciplined capital deployment.

Positive

• Effective hire date: January 1, 2026
• Experience: more than 30 years in healthcare and finance
• Relevant roles: big‑pharma P&L and medtech CEO experience
• Commercial focus: tasked to guide company to commercial launch

Negative

• COO role: designated as interim rather than permanent
• No specific launch timeline: only an intended commercial launch is stated

Key Figures

Q3 2025 net loss: $568,791 vs $644,291 prior year Operating expenses: $567,833 Cash balance: $92 +5 more

8 metrics

Q3 2025 net loss $568,791 vs $644,291 prior year Quarterly net loss reported in Q3 2025 10‑Q

Operating expenses $567,833 Q3 2025 operating expenses from 10‑Q

Cash balance $92 Cash at September 30, 2025 per 10‑Q

Total liabilities $2,179,731 Liabilities at September 30, 2025 per 10‑Q

Stockholders’ deficit $(2,172,730) Deficit at September 30, 2025 per 10‑Q

Nine‑month net loss $1,805,468 vs $3,453,800 prior year Nine months ended Q3 2025 per 10‑Q

Equity raises 2025 82,666 shares for $186,000; 12,000 shares for $27,000 Share sales disclosed in Q3 2025 10‑Q

Form 144 planned sales 77,400 shares, $247,680.00 Form 144 filed November 7, 2025

Market Reality Check

Price: $3.20 Vol: Pre‑news volume of 100 sh...

low vol

$3.20 Last Close

Volume Pre‑news volume of 100 shares is far below the 20‑day average of 1,577, indicating limited trading activity ahead of this announcement. low

Technical With price at $3.20 versus a 200‑day MA of $3.38, the stock was trading below its longer‑term trend and sat at its 52‑week low of $3.20, well under the $6.36 high.

Peers on Argus

RTGN showed a pre‑news decline of -9.86% while key Medical Devices peers were mi...

RTGN showed a pre‑news decline of -9.86% while key Medical Devices peers were mixed, with names like QTIH at -2.09%, BLOZF at -4.4%, and others flat. The magnitude of RTGN’s move appears more stock‑specific than sector‑driven.

Market Pulse Summary

This announcement highlights a significant management upgrade as RetinalGenix prepares for commercia...

Analysis

This announcement highlights a significant management upgrade as RetinalGenix prepares for commercialization of its retinal imaging and genetic‑testing platform. The appointment of a CFO and interim COO with broad Medtech and capital‑markets experience comes against a backdrop of tight liquidity, including cash of $92 and a stockholders’ deficit of $(2,172,730) in the latest 10‑Q. Investors may watch future filings, capital‑raising steps, and commercialization milestones to assess execution.

Key Terms

genetic testing, regulated medical devices, clinical development, reimbursement strategy, +2 more

6 terms

genetic testing medical

"developing ultra-high-resolution retinal imaging technology, combined with advanced genetic testing"

Genetic testing analyzes a person’s DNA to find changes that affect health, disease risk, or how someone may respond to medicines. For investors, these tests can create or shrink markets for diagnostics, drugs and personalized care, influence regulatory decisions and reimbursement, and alter company valuations—much like a weather forecast changes choices and risks for farmers preparing a crop.

regulated medical devices regulatory

"leader who understands regulated medical devices, clinical development, reimbursement strategy"

Products used to diagnose, monitor, or treat medical conditions that must meet government safety and performance standards before they can be sold or used. Think of them like cars that require inspection and a license to drive: regulatory approval and ongoing oversight affect how quickly a device reaches patients, how much it costs to bring to market, and the legal and financial risks investors face — approvals can boost value, while recalls or noncompliance can erode it.

clinical development medical

"understands regulated medical devices, clinical development, reimbursement strategy"

Clinical development is the process of testing a medical treatment in people to prove it is safe and works, moving from small early safety checks to larger trials that measure benefit and side effects. For investors it matters because each successful step reduces uncertainty and brings a product closer to regulatory approval and sales—like moving a prototype through road tests before mass production—while failures or delays can dramatically cut expected value.

reimbursement strategy financial

"clinical development, reimbursement strategy, and capital-market dynamics"

A reimbursement strategy is a company's plan for how payers — such as insurance companies, government programs, or employers — will pay for a product or service. Think of it like negotiating a price and payment method with a grocery store chain so shoppers can buy the item; for investors, a clear, realistic reimbursement strategy affects how many customers can afford the product, how fast revenue can grow, and how profitable the product will be over time.

capital-market dynamics financial

"clinical development, reimbursement strategy, and capital-market dynamics"

Capital-market dynamics are the forces and patterns that shape how money flows between savers, investors, companies and governments — including changes in interest rates, investor sentiment, supply and demand for stocks and bonds, and regulatory shifts. They matter to investors because these movements affect asset prices, the cost of raising capital and the risk of investments, much like tides determine where a boat can safely dock and how quickly it can leave harbor.

ai-enabled diagnostics technical

"execution across imaging hardware, AI-enabled diagnostics, genetics"

AI-enabled diagnostics are medical tools that use artificial intelligence to analyze patient data—like images, lab results or symptoms—to help detect, classify or predict health conditions. Investors care because these tools can speed up diagnosis, reduce costs and scale medical services much like a smart assistant speeds up routine tasks, but their commercial value depends on regulatory approval, clinical adoption and reimbursement, which affect revenue and risk.

AI-generated analysis. Not financial advice.

Zwerling expected to guide the Company to its commercial launch

APOLLO BEACH, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. [OTCQB: RTGN] (“RetinalGenix” or the “Company”), a company developing ultra-high-resolution retinal imaging technology, combined with advanced genetic testing, today announced the signing of an agreement to hire M. Cory Zwerling as its chief financial officer and interim chief operating officer, effective January 1, 2026. Mr. Zwerling brings more than three decades of global experience in healthcare, finance, and operations across pharmaceuticals, medical imaging, biotechnology, and digital health.

“As the Company prepares for commercialization, RetinalGenix requires a financial, strategic, and operational leader who understands regulated medical devices, clinical development, reimbursement strategy, and capital-market dynamics—and who can coordinate execution across imaging hardware, AI-enabled diagnostics, genetics, and both diagnostic and therapeutic programs.” said Jerry Katzman, MD, the Company’s Chairman, President, and CEO.

“Mr. Zwerling brings a distinctive combination of big-pharma P&L leadership, public-company governance, Medtech start-up execution, and hands-on CFO experience across healthcare technology. He has led global pharmaceutical and imaging divisions (President, Bristol-Myers Squibb Medical Imaging and other roles over his 18-year tenure at Bristol-Myers), founded and operated a healthcare IT/AI sleep-diagnostics company (CEO & co-founder, Serenium Inc), served as CEO of a medical-device venture (Zosano Pharmaceuticals), advised multiple health-technology companies, and held a public-company board seat. His background aligns directly with RetinalGenix’s strategic inflection point as the Company seeks to transition from R&D into early commercial operations. His leadership in global marketing, sales, international business management, and finance makes him uniquely equipped to guide the Company through its intended commercial launch while working to ensure disciplined capital deployment and long-term shareholder value creation,” continued Dr. Katzman.

“I'm honored to join the RetinalGenix team,” said Mr. Zwerling. “The company’s breakthrough technologies have exceptional potential to advance patient care while driving meaningful growth and value creation on a global scale.”

About RetinalGenix Technologies Inc.

RetinalGenix is an ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas by integrating genetic screening, advanced imaging, and therapeutic development. Its proprietary High-Resolution Retinal Imaging and RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular, and metabolic systems, as well as diabetic conditions, Alzheimer’s disease, Complex  Dementia, and Parkinson’s disease. RetinalGenix is also developing therapeutic drugs for dry age-related macular degeneration (dry AMD) and Alzheimer’s disease/dementia.

Safe Harbor Statement

This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements and include statements regarding the expected contribution of Mr. Zwerling, transitioning the Company from R&D into early commercial operations and ensuring disciplined capital deployment and long-term shareholder value creation. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, Mr. Zwerling’s ability to contribute to the Company as expected, the Company’s ability to successfully complete research and further development and commercialization of its products, the timing, cost and uncertainty of obtaining regulatory approvals for the Company’s products, the Company’s ability to protect its intellectual property, and the risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Media Contacts:
RetinalGenix Technologies Inc.
Media and Investor Relations
ir@retinalgenix.com
(800) 331-5446

FAQ

Who is M. Cory Zwerling and when does he start as RTGN CFO?

M. Cory Zwerling is a healthcare finance and operations executive who will start as RTGN CFO and interim COO on January 1, 2026.

What experience does RTGN say Zwerling brings to the CFO role?

RTGN highlighted Zwerling's 30+ years in pharmaceuticals, medical imaging, biotech, digital health, and public‑company governance.

How will Zwerling support RetinalGenix’s commercial plans for RTGN?

He is expected to guide the company toward an intended commercial launch, focusing on reimbursement strategy, clinical development, and capital deployment.

Is M. Cory Zwerling also taking an operational role at RTGN?

Yes. He will serve as both CFO and interim COO, combining financial and operational responsibilities.

Does the RTGN announcement include a specific commercialization timeline?

No. The company describes an intended commercial launch but does not provide specific dates or financial targets.

What prior leadership roles does RTGN cite for Zwerling relevant to RTGN (RTGN)?

The company cited his roles leading pharmaceutical and imaging divisions, founding a health IT/AI company, and serving as CEO of a medical‑device venture and a public‑company board member.